Celltech deal is shot in the arm for Lincoln
Lincoln Medical, based in Salisbury in the UK, has signed an agreement with Celltech under which Celltech will market and distribute Lincoln Medical's Anapen adrenaline auto-injector product for the emergency self-treatment of anaphylaxis in allergic patients. The agreement covers the UK, the Republic of Ireland and Germany.
Anaphylaxis is a life-threatening condition that can occur rapidly and without warning in allergic individuals. It requires treatment within minutes or death can result. The only effective treatment currently available is adrenaline. The Anapen product is a simple, pen-like device that patients carry with them at all times. It can be used within seconds and provides a rapidly effective injection of adrenaline at the press of a button. It is approved for marketing in the UK and is currently under regulatory review for other countries in Europe.
David Alcraft, chairman of Lincoln Medical, said: 'We are delighted to be working with Celltech. We are in discussions with potential distributors for other markets.'